IFNGR1 and neoplasm: To assess if combination therapy-improved mouse survival also depends on IL-7 and IFN-γ signalling in T cells, we followed long-term survival of CD45.1 tumour-bearing mice that were infused with WT, Ifngr1−/− or Il7r−/− total T cells.